Danica Pension Livsforsikringsaktieselskab Takes $173.67 Million Position in Boston Scientific Corporation $BSX

Danica Pension Livsforsikringsaktieselskab purchased a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,778,892 shares of the medical equipment provider’s stock, valued at approximately $173,673,000. Boston Scientific makes up 2.7% of Danica Pension Livsforsikringsaktieselskab’s investment portfolio, making the stock its 11th largest holding.

A number of other large investors also recently bought and sold shares of the business. Steph & Co. acquired a new stake in Boston Scientific in the third quarter valued at approximately $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific in the third quarter valued at approximately $25,000. Murphy & Mullick Capital Management Corp raised its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 170 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter valued at approximately $26,000. Finally, United Community Bank lifted its position in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BSX. Truist Financial cut their price target on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday, February 5th. BTIG Research reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, February 4th. Jefferies Financial Group reissued a “buy” rating on shares of Boston Scientific in a research note on Monday. Canaccord Genuity Group reduced their price target on shares of Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Finally, Robert W. Baird decreased their price target on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus price target of $107.32.

Boston Scientific Trading Up 2.0%

Shares of BSX opened at $71.19 on Wednesday. Boston Scientific Corporation has a 52-week low of $67.56 and a 52-week high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm’s fifty day moving average is $81.42 and its two-hundred day moving average is $92.71. The stock has a market cap of $105.64 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s quarterly revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains, with UBS keeping a “buy” rating despite trimming its price target — this preserves broker confidence and highlights upside vs. current levels. Benzinga
• Positive Sentiment: Market writeups note the pullback may be overdone given solid recent financials (quarterly revenue and EPS strength and guidance), which supports a rebound narrative among value- and momentum-seeking investors. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Positive Sentiment: News summaries explaining why BSX outpaced the market today help attract short-term flows and algos reacting to momentum and analyst notes. Why Boston Scientific (BSX) Outpaced the Stock Market Today
• Neutral Sentiment: Some investor notices and law-firm solicitations are informational and can amplify trading volume even if they don’t change fundamentals immediately; these items tend to keep the stock volatile near-term. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Multiple securities class-action filings and numerous law‑firm lead‑plaintiff solicitations allege disclosure problems around the U.S. Electrophysiology unit; this raises potential litigation risk, settlement exposure and near-term headline risk that can weigh on valuation. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Numerous law firms (Rosen, Pomerantz, Faruqi, Bernstein Liebhard, Robbins Geller, etc.) have issued alerts about the May 4 lead-plaintiff deadline — repetitive alerts keep legal risk top of mind for investors and can suppress sentiment until the cases are resolved or dismissed. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.